Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-22
    E.g., 2018-09-22

Articles

Pages

173342 items
11:58 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Deals

Corbus gets over 600 endocannabinoid-targeting compounds from Jenrin

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) acquired exclusive, worldwide rights to over 600 endocannabinoid system-targeting compounds from Jenrin Discovery LLC (Chadds Ford, Pa.) to treat inflammatory and fibrotic diseases. Jenrin will receive $250,000 upfront and is...
11:57 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Other News

American Thoracic Society releases updated guidelines for IPF diagnosis

The American Thoracic Society and other international respiratory societies released updated guidelines on Aug. 31 for the diagnosis of idiopathic pulmonary fibrosis (IPF), an indication for which there are only two approved therapies. The guidelines update...
11:27 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Deals

Ahead of Ph Ib data, Celgene declines to exercise option to OncoMed bispecific

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Sept. 20 that partner Celgene Corp. (NASDAQ:CELG) will not exercise its option to license OncoMed's bispecific antibody navicixizumab (OMP-305B83) as a result of "strategic product portfolio considerations." The bispecific targeting delta-like...
11:26 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Regulatory

FDA panel to discuss Alkermes' depression candidate

FDA's Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will meet Nov. 1 to discuss an NDA from Alkermes plc (NASDAQ:ALKS) for ALKS 5461 as an adjunct to treat major depressive...
10:38 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Deals

CRISPR partners with ViaCyte to develop immune-evasive pancreatic cells

CRISPR Therapeutics AG (NASDAQ:CRSP) and ViaCyte Inc. (San Diego, Calif.) partnered to develop a gene edited immune-evasive pancreatic stem cell line as an islet cell replacement therapy that would not require immunosuppression and could potentially...
10:38 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Sosei, Allergan to delay trials of dementia candidate

Sosei Group Corp. (Tokyo:4565) and partner Allergan plc (NYSE:AGN) have suspended clinical development of neurodegenerative candidate HTL0018318 to investigate a toxicity signal -- a rare tumor -- found in a non-human primate treated with the...
10:38 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

uBiome moving into therapeutics with $83M series C

Microbiome tech and diagnostic company uBiome Inc. (San Francisco, Calif.) raised $83 million in a series C round led by OS Fund to expand into drug research and development using its patented microbiome assets. Also...
10:37 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million on Sept. 20 in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and activator...
10:37 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Amended Offerings

Sutro amends IPO

Autoimmune and cancer company Sutro Biopharma Inc. (South San Francisco, Calif.) amended on Sept. 17 its IPO on NASDAQ and now plans to sell 5 million shares at $14-$16. At the midpoint, the company would...
10:37 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Other Financial News

Hillhouse closes $10.6B fund

Hillhouse Capital said it closed its oversubscribed Hillhouse Fund IV with $10.6 billion. The fund will invest in healthcare, consumer technology and services with a focus on Asia. Hillhouse’s Josh Gartner told BioCentury the fund does...

Pages